U.S. Markets open in 1 min
  • S&P Futures

    4,403.75
    -10.50 (-0.24%)
     
  • Dow Futures

    34,906.00
    -128.00 (-0.37%)
     
  • Nasdaq Futures

    15,106.00
    -11.75 (-0.08%)
     
  • Russell 2000 Futures

    2,195.50
    -17.90 (-0.81%)
     
  • Crude Oil

    71.93
    +0.02 (+0.03%)
     
  • Gold

    1,804.30
    +5.10 (+0.28%)
     
  • Silver

    25.19
    -0.13 (-0.51%)
     
  • EUR/USD

    1.1827
    +0.0020 (+0.1656%)
     
  • 10-Yr Bond

    1.2460
    -0.0300 (-2.35%)
     
  • Vix

    18.67
    +1.47 (+8.55%)
     
  • GBP/USD

    1.3826
    +0.0002 (+0.0152%)
     
  • USD/JPY

    109.8920
    -0.4830 (-0.4376%)
     
  • BTC-USD

    38,429.86
    +114.32 (+0.30%)
     
  • CMC Crypto 200

    913.83
    -1.66 (-0.18%)
     
  • FTSE 100

    6,998.96
    -26.47 (-0.38%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

FibroGen In-Licenses Three HiFiBiO Programs For Cancer, Autoimmune Settings

·1 min read
  • FibroGen Inc (NASDAQ: FGEN) and HiFiBiO Therapeutics have entered into a licensing agreement for three programs in the immuno-oncology and autoimmune space.

  • FibroGen exclusively in-licenses HiFiBiO's Galectin-9 program and obtains an exclusive option to their CXCR5 and CCR8 programs.

  • Under the terms of the agreement, FibroGen will make a $25 million upfront payment to HiFiBiO and payments upon option exercise.

  • In addition, HiFiBiO may receive up to a total of an additional $1.1 billion in milestone payments across all three programs.

  • HiFiBiO will also be eligible to receive royalties based upon worldwide net sales.

  • The lead product candidate in the Galectin-9 program is expected to enter clinical development in the Q1 of 2023.

  • The lead candidates from the CXCR5 and CCR8 programs will enter the clinic by mid-2023.

  • Price Action: FGEN shares closed at $25.84 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.